Objective:This single site study is designed to describe and measure the efficacy of oral versus vaginal dosing of TFV-based products, specifically emtricitabine/tenofovir disoproxil fumarate oral tablets (Truvada) vs tenofovir intravaginal rings (IVR).
Study Design:Open label
Arms and Assigned Interventions
DescriptionThe participant will wear the intravaginal ring consecutively for 14 days and nights.
Mode of DeliveryRing
DescriptionThe participant will take the tablet for 14 days.
Mode of DeliveryTablet
Official Code: NCT02722343
April 7, 2016
August 5, 2016
Age range: 18 Years ↔ 50 Years